 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ:XNCR, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Boston, November 10-12, 2022. Data from the first patients enrolled in a Phase 2 study of vudalimab, Xencors selective PD-1 x CTLA-4 bispecific antibody, plus chemo 